Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 12/20 | 0.52 |
| ▸ | LPAR5 | Q9H1C0 | 11/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540766 | 0.84 | LPAR1 (0.57) | LPAR1LPAR5KDM4ELMNAGAA | |
| SCHEMBL6539665 | 0.84 | LPAR1 (0.57) | LPAR1LPAR5KDM4E | |
| SCHEMBL6799225 | 0.83 | LPAR1 (0.43) | LPAR1LPAR5PTGESLMNAGAA | |
| SCHEMBL6541221 | 0.81 | LPAR1 (0.52) | LPAR1LPAR5MMP2NR3C1PTGES | |
| SCHEMBL6540935 | 0.81 | LPAR1 (0.48) | LPAR1LPAR5MMP2KDM4ELMNA | |
| SCHEMBL6677473 | 0.80 | LPAR1 (0.60) | LPAR1LPAR5PTGES | |
| SCHEMBL6540825 | 0.79 | OPRK1 (0.50) | LPAR1LPAR5 | |
| SCHEMBL6540096 | 0.78 | LPAR1 (0.54) | LPAR1LPAR5MMP2NR3C1PTGES | |
| SCHEMBL6540146 | 0.78 | LPAR1 (0.52) | LPAR1LPAR5MMP2PTGES | |
| SCHEMBL6800067 | 0.78 | LPAR1 (0.49) | LPAR1LPAR5CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | LPAR1 362/4885LPAR5 719/4885MMP2 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.